Josephine Mauskopf

Summary

Affiliation: RTI International
Country: USA

Publications

  1. doi request reprint Treatment sequencing after failure of the first biologic in cost-effectiveness models of psoriasis: a systematic review of published models and clinical practice guidelines
    Josephine Mauskopf
    RTI Health Solutions, 3040 Cornwallis Road, Research Triangle Park, NC, 27709, USA
    Pharmacoeconomics 32:395-409. 2014
  2. doi request reprint Comparative cost-effectiveness analysis of voriconazole and fluconazole for prevention of invasive fungal infection in patients receiving allogeneic hematopoietic cell transplants
    Josephine Mauskopf
    Health Economics, RTI Health Solutions, Research Triangle Park, NC 12194, USA
    Am J Health Syst Pharm 70:1518-27. 2013
  3. pmc Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement
    Don Husereau
    Institute of Health Economics, Edmonton, Canada
    Cost Eff Resour Alloc 11:6. 2013
  4. pmc Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement
    Don Husereau
    Institute of Health Economics, Edmonton, Canada
    BMC Med 11:80. 2013
  5. pmc Relationship between financial impact and coverage of drugs in Australia
    Josephine Mauskopf
    RTI Health Solutions, Research Triangle Park, NC 27709, USA
    Int J Technol Assess Health Care 29:92-100. 2013
  6. doi request reprint Drug reimbursement recommendations by the National Institute for Health and Clinical Excellence: have they impacted the National Health Service budget?
    Josephine Mauskopf
    RTI Health Solutions, Research Triangle Park, NC 27709, USA
    Health Policy 110:49-59. 2013
  7. doi request reprint The burden of influenza complications in different high-risk groups: a targeted literature review
    Josephine Mauskopf
    RTI Health Solutions, Research Triangle Park, NC 27709, USA
    J Med Econ 16:264-77. 2013
  8. pmc Immunonutrition for patients undergoing elective surgery for gastrointestinal cancer: impact on hospital costs
    Josephine A Mauskopf
    RTI Health Solutions, Durham, NC, USA
    World J Surg Oncol 10:136. 2012
  9. doi request reprint Categorization of methods used in cost-effectiveness analyses of vaccination programs based on outcomes from dynamic transmission models
    Josephine Mauskopf
    RTI Health Solutions, 3040, Cornwallis Road, Research Triangle Park, NC 27709, USA
    Expert Rev Pharmacoecon Outcomes Res 12:357-71. 2012
  10. doi request reprint Cost-effectiveness of prasugrel in a US managed care population
    Josephine A Mauskopf
    RTI Health Solutions, Research Triangle Park, NC 27709, USA
    J Med Econ 15:166-74. 2012

Detail Information

Publications34

  1. doi request reprint Treatment sequencing after failure of the first biologic in cost-effectiveness models of psoriasis: a systematic review of published models and clinical practice guidelines
    Josephine Mauskopf
    RTI Health Solutions, 3040 Cornwallis Road, Research Triangle Park, NC, 27709, USA
    Pharmacoeconomics 32:395-409. 2014
    ..To analyse the treatment sequencing assumptions after failure on a first-line biologic in cost-effectiveness models of treatment of moderate to severe plaque psoriasis, and to compare them with the most recent treatment guidelines...
  2. doi request reprint Comparative cost-effectiveness analysis of voriconazole and fluconazole for prevention of invasive fungal infection in patients receiving allogeneic hematopoietic cell transplants
    Josephine Mauskopf
    Health Economics, RTI Health Solutions, Research Triangle Park, NC 12194, USA
    Am J Health Syst Pharm 70:1518-27. 2013
    ..The cost-effectiveness of voriconazole versus fluconazole prophylaxis against fungal infections in hematopoietic cell transplant (HCT) recipients is investigated...
  3. pmc Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement
    Don Husereau
    Institute of Health Economics, Edmonton, Canada
    Cost Eff Resour Alloc 11:6. 2013
    ..We encourage other journals and groups, to endorse CHEERS. The author team plans to review the checklist for an update in five years...
  4. pmc Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement
    Don Husereau
    Institute of Health Economics, Edmonton, Canada
    BMC Med 11:80. 2013
    ..We encourage other journals and groups, to endorse CHEERS. The author team plans to review the checklist for an update in five years...
  5. pmc Relationship between financial impact and coverage of drugs in Australia
    Josephine Mauskopf
    RTI Health Solutions, Research Triangle Park, NC 27709, USA
    Int J Technol Assess Health Care 29:92-100. 2013
    ..The aim of this study was to estimate the relationship between the financial impact of a new drug and the recommendation for reimbursement by the Australian Pharmaceutical Benefits Advisory Committee (PBAC)...
  6. doi request reprint Drug reimbursement recommendations by the National Institute for Health and Clinical Excellence: have they impacted the National Health Service budget?
    Josephine Mauskopf
    RTI Health Solutions, Research Triangle Park, NC 27709, USA
    Health Policy 110:49-59. 2013
    ..Determine whether reimbursement restrictions recommended by the National Institute for Health and Clinical Excellence (NICE) have impacted the United Kingdom (UK) National Health Service (NHS) budget...
  7. doi request reprint The burden of influenza complications in different high-risk groups: a targeted literature review
    Josephine Mauskopf
    RTI Health Solutions, Research Triangle Park, NC 27709, USA
    J Med Econ 16:264-77. 2013
    ....
  8. pmc Immunonutrition for patients undergoing elective surgery for gastrointestinal cancer: impact on hospital costs
    Josephine A Mauskopf
    RTI Health Solutions, Durham, NC, USA
    World J Surg Oncol 10:136. 2012
    ..The objective of the study was to determine the impact on hospital costs of immunonutrition formulas used in patients undergoing elective surgery for gastrointestinal cancer...
  9. doi request reprint Categorization of methods used in cost-effectiveness analyses of vaccination programs based on outcomes from dynamic transmission models
    Josephine Mauskopf
    RTI Health Solutions, 3040, Cornwallis Road, Research Triangle Park, NC 27709, USA
    Expert Rev Pharmacoecon Outcomes Res 12:357-71. 2012
    ..Sensitivity analyses for time horizon or number of cohorts considered should be routinely performed...
  10. doi request reprint Cost-effectiveness of prasugrel in a US managed care population
    Josephine A Mauskopf
    RTI Health Solutions, Research Triangle Park, NC 27709, USA
    J Med Econ 15:166-74. 2012
    ..Decision-makers in the US may be interested in the applicability to their populations of cost-effectiveness results generated from clinical trial populations...
  11. doi request reprint Cost-effectiveness of combination therapy with etravirine in treatment-experienced adults with HIV-1 infection
    Josephine Mauskopf
    RTI Health Solutions, Research Triangle Park, North Carolina, USA
    AIDS 26:355-64. 2012
    ....
  12. doi request reprint Differences among formulary submission guidelines: implications for health technology assessment
    Josephine Mauskopf
    RTI Health Solutions
    Int J Technol Assess Health Care 27:261-70. 2011
    ....
  13. doi request reprint A review of the methods used to estimate the cost of Alzheimer's disease in the United States
    Josephine Mauskopf
    Health Economics, RTI Health Solutions, Research Triangle Park, NC, USA
    Am J Alzheimers Dis Other Demen 26:298-309. 2011
    ..BACKGROUN/RATIONALE: To determine the suitability of published estimates of the US cost of Alzheimer's disease (AD) for use in cost-effectiveness models for new AD treatments...
  14. doi request reprint Cost effectiveness of darunavir/ritonavir in highly treatment-experienced, HIV-1-infected adults in the USA
    Josephine Mauskopf
    RTI Health Solutions, Research Triangle Park, North Carolina, USA
    Pharmacoeconomics 28:83-105. 2010
    ..This study estimates the cost effectiveness of darunavir with ritonavir (DRV/r) in this population over 5-year and lifetime time horizons in the USA...
  15. doi request reprint A review of economic evaluations of darunavir boosted by low-dose ritonavir in treatment-experienced persons living with HIV infection
    Josephine Mauskopf
    RTI Health Solutions, Research Triangle Park, NC, USA
    Pharmacoeconomics 28:1-16. 2010
    ....
  16. ncbi request reprint Alzheimer's disease: the strength of association of costs with different measures of disease severity
    J Mauskopf
    RTI Health Solutions, 200 Park Offices Drive, Research Triangle Park, NC 27709, USA
    J Nutr Health Aging 14:655-63. 2010
    ..To identify Alzheimer's disease (AD) severity measures for use in cost-effectiveness models that effectively capture the impact of AD on costs...
  17. doi request reprint Cost effectiveness of tiotropium for chronic obstructive pulmonary disease: a systematic review of the evidence
    Josephine A Mauskopf
    RTI Health Solutions, Research Triangle Park, NC 27709, USA
    J Med Econ 13:403-17. 2010
    ..Tiotropium has been shown to reduce exacerbations and improve quality of life for patients with chronic obstructive pulmonary disease (COPD), a lung disease characterized by a persistent and progressive airflow limitation...
  18. ncbi request reprint The economic impact of uterine fibroids in the United States: a summary of published estimates
    Josephine Mauskopf
    RTI Health Solutions, 3040 Cornwallis Road, Research Triangle Park, NC 27709, USA
    J Womens Health (Larchmt) 14:692-703. 2005
    ..To present a summary of published estimates of the economic burden of uterine fibroids in the United States and identify areas for additional research...
  19. ncbi request reprint Drug persistency patterns for patients treated with rivastigmine or donepezil in usual care settings
    Josephine A Mauskopf
    Health Economics RTI Health Solutions, 3040 Cornwallis Rd, PO Box 12194, Research Triangle Park, NC 27709, USA
    J Manag Care Pharm 11:231-51. 2005
    ..To compare levels of persistency with 2 cholinesterase (ChE) inhibitors--rivastigmine and donepezil--for the treatment of Alzheimer's disease (AD) through the use of administrative claims data...
  20. ncbi request reprint Cost-effectiveness league tables: valuable guidance for decision makers?
    Josephine Mauskopf
    Health Economics and Outcomes Strategy, RTI Health Solutions, Research Triangle Park, North Carolina 27709, USA
    Pharmacoeconomics 21:991-1000. 2003
    ..In addition, a central repository for reference case expanded league tables is suggested so that decision makers can use them more effectively and more consistently...
  21. ncbi request reprint Estimating the costs and benefits of new drug therapies: atypical antipsychotic drugs for schizophrenia
    Josephine Mauskopf
    RTI Health Solutions, Research Triangle Park, NC 27709, USA
    Schizophr Bull 28:619-35. 2002
    ..Thus, switching to atypical drugs will likely reduce total medical care costs and decrease other disease burdens for people with schizophrenia, their families, and society...
  22. doi request reprint Nonresponse, partial response, and failure to achieve remission: humanistic and cost burden in major depressive disorder
    Josephine A Mauskopf
    RTI Health Solutions, Research Triangle Park, 200 Park Drive, Research Triangle Park, NC 27709, USA
    Depress Anxiety 26:83-97. 2009
    ..To characterize the spectrum of clinical outcomes achieved with depression treatment and the associated impact on quality of life (QOL), functional status, overall well-being, health-care costs, and productivity...
  23. doi request reprint Adherence to guidelines for sensitivity analysis: cost-effectiveness analyses of dual oral antiplatelet therapy
    Josephine A Mauskopf
    RTI Health Solutions, Research Triangle Park, NC 27709 2194, USA
    J Med Econ 12:141-53. 2009
    ..The objective of this paper is to examine the extent to which published sensitivity analyses addressing this uncertainty adhere to Health Technology Assessment (HTA) guidelines...
  24. ncbi request reprint HIV antiretroviral treatment: early versus later
    Josephine Mauskopf
    RTI Health Solutions, Research Triangle Park, NC 27709, USA
    J Acquir Immune Defic Syndr 39:562-9. 2005
    ..This report uses a modeling approach to compare starting HAART at a mean CD4+ T-cell count greater than 350 cells/microL (early) versus less than 350 cells/microL but greater than 200 cells/microL (later)...
  25. doi request reprint US cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial
    Anita Brogan
    RTI Health Solutions, Research Triangle Park, North Carolina, USA
    Pharmacoeconomics 28:129-46. 2010
    ..This population had less advanced HIV disease and a broader range of previous PI exposure/failure (0 - ≥ 2 PIs) at enrollment than those in the darunavir phase IIb POWER trials...
  26. ncbi request reprint Uterine fibroids: a review of health-related quality of life assessment
    Valerie S L Williams
    RTI Health Solutions, Research Triangle Park, NC, 27709 2194, USA
    J Womens Health (Larchmt) 15:818-29. 2006
    ..To summarize the literature describing the impact of uterine fibroids on health-related quality of life (HRQOL), the measures used to assess HRQOL, and related areas for future research...
  27. doi request reprint Model-based cost-effectiveness analyses for the treatment of acute stroke events: a review and summary of challenges
    Stephanie R Earnshaw
    RTI Health Solutions, Research Triangle Park, NC 27709 2194, USA
    Value Health 12:507-20. 2009
    ....
  28. ncbi request reprint Cost-effectiveness of live-attenuated influenza vaccine, trivalent in preventing influenza in young children attending day-care centres
    Clare L Hibbert
    RTI Health Solutions, Williams House, Manchester Science Park, Lloyd Street North, Manchester M15 6SE, United Kingdom
    Vaccine 25:8010-20. 2007
    ..2%; placebo, 13.4%), vaccination saved US$ 5.47 per child in societal costs. In the high attack-rate season (vaccinated, 4.7%; placebo, 32.1%), vaccination led to a societal costs savings of US$ 144.44 per child...
  29. ncbi request reprint A Monte Carlo simulation for modelling outcomes of AIDS treatment regimens
    Anke Richter
    RTI Health Solutions, Research Triangle Park, North Carolina 27709, USA
    Pharmacoeconomics 20:215-24. 2002
    ..The model is flexible and permits adaptation to the changing treatment environment in HIV infection...
  30. pmc Do different clinical evidence bases lead to discordant health-technology assessment decisions? An in-depth case series across three jurisdictions
    Daryl S Spinner
    RTI Health Solutions, Research Triangle Park, NC, USA
    Clinicoecon Outcomes Res 5:69-85. 2013
    ..In this study, we performed nine in-depth case studies to assess whether different clinical evidence bases may have influenced listing recommendations made by PBAC, CDR, and NICE...
  31. ncbi request reprint Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis
    Josephine A Mauskopf
    RTI Health Solutions, Research Triangle Park, NC, USA
    Value Health 10:336-47. 2007
    ..The objective of this report is to present guidance on methodologies for those undertaking such analyses or for those reviewing the results of such analyses...
  32. ncbi request reprint Minimizing resistance consequences after virologic failure on initial combination therapy: a systematic overview
    John A Bartlett
    AIDS Research and Treatment Center, Duke University Medical Center, Durham, NC, USA
    J Acquir Immune Defic Syndr 41:323-31. 2006
    ..To identify optimal first-line therapies based on the rate of virologic success (VS) and the preservation of future treatment options in antiretroviral therapy (ART)-naive subjects...
  33. ncbi request reprint Optimal assignment of treatments to health states using a Markov decision model: an introduction to basic concepts
    Mohan V Bala
    Centocor Inc, Malvern, Pennsylvania 19355, USA
    Pharmacoeconomics 24:345-54. 2006
    ..Even with its limitations, Markov decision models offer an opportunity for health economists to inform healthcare decision-makers on how to modify current treatment pathways to incorporate new treatments as they become available...
  34. ncbi request reprint Conditions for the near equivalence of cost-effectiveness and cost-benefit analyses
    Mohan V Bala
    Centocor, Inc, Malvern, Pennsylvania 19355, USA
    Value Health 5:338-46. 2002
    ..We also examine the equivalence of two different definitions of CEA provided in the literature and discuss the problems that could arise when there are multiple optima...